Elsevier

Vaccine

Volume 33, Issue 48, 27 November 2015, Pages 6596-6603
Vaccine

A new EV71 VP3 epitope in norovirus P particle vector displays neutralizing activity and protection in vivo in mice

https://doi.org/10.1016/j.vaccine.2015.10.104Get rights and content

Highlights

Abstract

Enterovirus 71 (EV71) and Coxsackievirus A16 (CVA16), as the main agents causing hand, foot and mouth disease (HFMD), have become a serious public health concern in the Asia-Pacific region. Recently, various neutralizing B cell epitopes of EV71 were identified as targets for promising vaccine candidates. Structural studies of Picornaviridae indicated that potent immunodominant epitopes typically lie in the hypervariable loop of capsid surfaces. However, cross-neutralizing antibodies and cross-protection between EV71 and CVA16 have not been observed. Therefore, we speculated that divergent sequences of the two viruses are key epitopes for inducing protective neutralizing responses. In this study, we selected 10 divergent epitope candidates based on alignment of the EV71 and CVA16 P1 amino acid sequences using the Multalin interface page, and these epitopes are conserved among all subgenotypes of EV71. Simultaneously, by utilizing the norovirus P particle as a novel vaccine delivery carrier, we identified the 71-6 epitope (amino acid 176–190 of VP3) as a conformational neutralizing epitope against EV71 in an in vitro micro-neutralization assay as well as an in vivo protection assay in mice. Altogether, these results indicated that the incorporation of the 71-6 epitope into the norovirus P domain can provide a promising candidate for an effective synthetic peptide-based vaccine against EV71.

Introduction

Enterovirus 71 (EV71) is the main causative agent of hand, foot and mouth disease (HFMD) and has been associated with severe neurological diseases resulting in high mortality in young children under the age of six [1], [2], [3]. EV71 was first isolated in mainland China in 1987 [4]. From 2008 to 2011, HFMD claimed 1893 lives in mainland China, and these deaths were caused mainly by EV71 infection [5], [6], [7]. Three candidate vaccines against EV71 have been developed and evaluated in phase III trials in mainland China, demonstrating good safety profiles and abilities to mediate protective effects [8], [9], and antiviral drug studies have also been reported [10], [11], [12], [13], [14], [15]. However, no vaccine against EV71 is currently available [16].

EV71 is a small, non-enveloped, positive-stranded RNA virus with a genome size of about 7.4 kb, which is encapsidated within an icosahedral capsid, and the four viral structural proteins (VP1, VP2, VP3 and VP4) function as a single structural subunit, the protomer. Five protomers in turn form a pentamer, twelve of which can self-assemble into a naturally native virion [16], [17], [18], [19]. VP1, VP2 and VP3 are arranged at the surface of the virion and therefore are exposed to immune pressure, while VP4 is located internally [20], [21].

Analysis of the crystal structure of EV71 to 3.8 Å resolution demonstrated that the EV71 virion has a quasi-T = 3 symmetry with β-sandwich “jelly-roll” folds like other picornaviruses. The most variable regions of picornavirus virions are the loops exposed on the virion surface that are also important neutralizing immunogenic sites [22], [23], [24]. For example, Foo et al. reported that residues 208–222 (GH loop) of VP1, which is the most surface exposed viral protein, as an important neutralizing epitope of EV71 [25]. Additionally, Xu et al. identified that residues 141–150 of VP2, alongside the VP2 EF loop, as an EV71 neutralization epitope [26]. Therefore, a peptide-based vaccine containing a neutralizing epitope is considered an attractive and promising approach to stimulate an effective and specific protective immune response [25]. However, small synthetic peptides containing linear B-cell epitopes are usually poorly immunogenic [27], [28]. Virus-like particles (VLPs), such as Hepatitis B core antigen (HBc) VLPs, human papillomavirus (HPV) VLPs and modular VLPs, as well as norovirus P particles [16], [29], [30], [31], [32], [33], [34], display morphologies similar to natural virions and have proven to be optimal delivery systems for the presentation of epitopes to the immune system. With the ability to efficiently interact with antigen-presenting cells, VLPs can display heterologous epitopes at high density and maximize the immunogenic and protective potential of neutralizing epitopes.

The capsid protein of norovirus, belonging to the Caliciviridae family, is composed of a shell (S) domain and protrusion (P) domain [35], [36]. When expressed alone, the P domain can assemble spontaneously into P particles with a T = 1 octahedral (24-mers) symmetry. As a new platform for displaying foreign antigen epitopes, norovirus P particles offer several advantages. They can be produced in Escherichia coli and Pichia pastoris (yeast) easily and stably [20], [37]. P particles also can enhance immune responses to the inserted foreign antigen [29], [36], [38], [39]. Conceivably, P particles can be applied as a platform for novel vaccine development against various viral and bacterial pathogens.

Enterovirus 71 (EV71) and coxsackievirus A16 (CVA16) both belong to the genus Enterovirus within the family Picornaviridae [40], but EV71 vaccines have failed to prevent CVA16 infections [41]. By protein alignment of these two viruses, we found differences in amino acids concentrated on particular regions in different loops based on the crystal structure [24], [42]. Therefore, we hypothesized that the regions of differential amino acids concentrated on the surface-exposed loops may be immunodominant and antigenic sites. This hypothesis was confirmed by different genotypes of HPV [43], [44]. In this study, conserved regions of EV71 were selected based on alignment of EV71 and CVA16 P1 amino acid sequences [7], [45], [46], as well as the reported major surface-exposed loop domains of EV71 [42]. P particle-EV71 epitope chimeric vaccines were constructed by insertion of selected EV71 epitopes, including the previously identified neutralizing linear epitope SP70 (208–222 of VP1), into loop 2 of the norovirus P particle [25]. We evaluated the potential of the norovirus P particle as a carrier for delivery of EV71 epitopes to achieve enhanced immunogenicity and protection against viral infection in the mouse model. Analysis of sera from immunized mice led to the identification of the neutralizing epitope 71-6 (residues 176–190) within the VP3 protein of EV71. Study of the crystal structure of EV71 have demonstrated that the 71-6 epitope of the GH loop in VP3 could generate potent neutralizing antibodies [24], [47]. Immunized mice developed significantly increased immune responses, and 100% of those animals survived after a lethal challenge with the EV71 virus. These results led to the identification of anew cross-neutralizing epitope (residues 176–190) of VP3 utilizing a P particle carrier.

Section snippets

Cell lines, media and viruses

Human rhabdomyosarcoma (RD) cells, RD-SCARB2 (RDS) and 293-SCARB2 (293S) cell lines were cultured and EV71 C4 strain was propagated as described previously [46], [48], [49].

Peptides, inactivated EV71 and VLP vaccines

Keyhole Limpet Hemocyanin (KLH) conjugated synthetic 71-6 peptide (designated here as pep. 71-6) from GL Biochem. Ltd. (Shanghai, China) was dissolved in PBS to 1 mg/ml [49] and stored at −80 °C. Production and purification of inactivated EV71 and VLP vaccines were described previously [46].

Selection of epitopes and construction of expression vectors

The expression vector pET28a (+)-P

Expression and purification of chimeric P particles displaying EV71 epitopes

All purified P particle–EV71 epitope proteins (i.e., norovirus chimeric proteins) were subjected to SDS-PAGE analysis, which showed that their inferred molecular masses (∼37 kDa) were slightly higher than that of the unmodified P particles (∼35 kDa) (Figure S2B). Concentrations of the chimeric proteins (yields ranging 5–10 mg/L) were determined by using the Odyssey Infrared Imaging System (Fig. S2C), and all proteins reacted with the anti-His mAb in Western blot assays (Fig. S2D).

Antibody response following PP-EV71 epitope protein immunization

Groups of five

Discussion

In previous studies, a cross-protective vaccine against EV71 infections was developed based on the peptide selection method, and two conserved linear neutralizing epitopes (SP70 and SP55) belonging to the VP1 subunit were identified [25], [61]. Another VP2 peptide also was demonstrated as a potential neutralization site. However, based on the EV71 crystal structural analysis, the VP3 subunit was thought to have major antigen clusters, but it was not described as having neutralizing antibody

Conclusions

We have successfully identified residues 176–190 within the VP3 capsid protein of EV71 as a conformational neutralizing epitope. Our results suggested that the chimeric protein PP-71-6 might provide an opportunity for the design of a dual vaccine candidate against both EV71 and norovirus. Simultaneously, the discovery of the amino acids 176–190 of VP3 as a conformational neutralizing epitope provides valuable information for the production of mAbs and development of a vaccine for HFMD.

References (64)

  • F. Schodel et al.

    Hybrid hepatitis B virus core antigen as a vaccine carrier moiety: I. Presentation of foreign epitopes

    J Biotechnol

    (1996)
  • J.Z. Bereszczak et al.

    Structure, stability and dynamics of norovirus P domain derived protein complexes studied by native mass spectrometry

    J Struct Biol

    (2012)
  • M. Xia et al.

    A candidate dual vaccine against influenza and noroviruses

    Vaccine

    (2011)
  • C.C. Liu et al.

    Prospect and challenges for the development of multivalent vaccines against hand, foot and mouth diseases

    Vaccine

    (2014)
  • B. Bishop et al.

    Crystal structures of four types of human papillomavirus L1 capsid proteins: understanding the specificity of neutralizing monoclonal antibodies

    J Biol Chem

    (2007)
  • X. Li et al.

    Establishment of cell lines with increased susceptibility to EV71/CA16 by stable overexpression of SCARB2

    Virol J

    (2013)
  • Q. Liu et al.

    Detection, characterization and quantitation of coxsackievirus A16 using polyclonal antibodies against recombinant capsid subunit proteins

    J Virol Methods

    (2011)
  • C.C. Liu et al.

    Identification and characterization of a cross-neutralization epitope of enterovirus 71

    Vaccine

    (2011)
  • J. Jin et al.

    Development of a coxsackievirus A16 neutralization assay based on pseudoviruses for measurement of neutralizing antibody titer in human serum

    J Virol Methods

    (2013)
  • E.J. Bek et al.

    Formalin-inactivated vaccine provokes cross-protective immunity in a mouse model of human enterovirus 71 infection

    Vaccine

    (2011)
  • Q. Liu et al.

    A virus-like particle vaccine for coxsackievirus A16 potently elicits neutralizing antibodies that protect mice against lethal challenge

    Vaccine

    (2012)
  • A.B. Kolpe et al.

    Display of enterovirus 71 VP1 on baculovirus as a type II transmembrane protein elicits protective B and T cell responses in immunized mice

    Virus Res

    (2012)
  • Z. Ku et al.

    A virus-like particle based bivalent vaccine confers dual protection against enterovirus 71 and coxsackievirus A16 infections in mice

    Vaccine

    (2014)
  • H.Y. Li et al.

    Virus-like particles for enterovirus 71 produced from Saccharomyces cerevisiae potently elicits protective immune responses in mice

    Vaccine

    (2013)
  • D.G. Foo et al.

    Passive protection against lethal enterovirus 71 infection in newborn mice by neutralizing antibodies elicited by a synthetic peptide

    Microbes Infect

    (2007)
  • A. Hagiwara et al.

    Epidemic of hand, foot and mouth disease associated with enterovirus 71 infection

    Intervirology

    (1978)
  • B. Somasundaram et al.

    Development of picornavirus-like particle vaccines

    Pharm Bioprocess

    (2015)
  • S.M. Wang et al.

    Reemerging of enterovirus 71 in Taiwan: the age impact on disease severity

    Eur J Clin Microbiol Infect Dis

    (2012)
  • X. Tan et al.

    The persistent circulation of enterovirus 71 in People's Republic of China: causing emerging nationwide epidemics since 2008

    PLoS ONE

    (2011)
  • H. Zhang et al.

    Analysis of cross-reactive neutralizing antibodies in human HFMD serum with an EV71 pseudovirus-based assay

    PLoS ONE

    (2014)
  • Z. Liang et al.

    Progress on the research and development of human enterovirus 71 (EV71) vaccines

    Front Med

    (2013)
  • P. Chong et al.

    Production of EV71 vaccine candidates

    Hum Vaccin Immunother

    (2012)
  • Cited by (28)

    • Norovirus-VLPs expressing pre-erythrocytic malaria antigens induce functional immunity against sporozoite infection

      2022, Vaccine
      Citation Excerpt :

      Furthermore, the P-particle can be easily produced in E. coli and P. pastoris and is extremely stable [52], making it an optimal alternative for multi-antigen, high-density epitope display. To date, these 24-valent P nanoparticles have been successfully engineered to display foreign antigens of infectious and non-infectious diseases, including rotavirus [49], influenza [53,54], enterovirus 71 [55], HIV-1 [56,57], and Alzheimer’s disease [58,59]. Here, we evaluate recombinant Norovirus P-particle constructs engineered to display epitopes from protective malaria antigens, PfCelTOS and PfCSP, for their immunogenicity and ability to confer protection against heterologous challenge in a murine model.

    • Antigenicity and immunogenicity of HA2 and M2e influenza virus antigens conjugated to norovirus-like, VP1 capsid-based particles by the SpyTag/SpyCatcher technology

      2022, Virology
      Citation Excerpt :

      Despite extensive research on the potential of various nanoparticles acting as vaccine platforms, the applicability of the VLPs formed by a VP1 capsid protein of NoV as antigen carriers has not been thoroughly studied. However, the successful presentation of several foreign antigens inserted into the surface loops of NoV VP1 capsid-derived subviral P domain (Tan et al., 2011; Jiang et al., 2015; Xia et al., 2011) or the hinge of S domain (Xia et al., 2018) supports the potential of NoV VLPs to act as a vaccine platform. These VLPs can be easily produced in baculovirus-insect cell expression system at high quantities.

    • Two cases of hand, foot and mouth disease caused by enterovirus A71 after vaccination

      2021, International Journal of Infectious Diseases
      Citation Excerpt :

      Foo et al. (2007) showed that SP55 (position 163–177, amino acid sequence PESRESLAWQTATNP) of VP1 could be a potential epitope. Jiang et al. (2015) identified the 71-6 epitope (position 176–190 of VP3, amino acid sequence HYRAHARDGVFDYYT) as a conformational neutralizing epitope against EVA71. The present study found amino acid mutations of the SP55 (position 729, Figure 5a) and 71-6 (position 500, Figure 5a) epitopes of the KM18A and KM18B strains.

    View all citing articles on Scopus
    View full text